The combi-targeting concept: Evidence for the formation of a novel inhibitor in vivo

Anti-Cancer Drugs

Volumn 17, Issue 2, 2006, Pages 165-171

  Merayo, Nuria ^a   Rachid, Zakaria ^a   Qiu, Qiyu ^a   Brahimi, Fouad ^a   Jean Claude, Bertrand J ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Combi molecule; Epidermal growth factor receptor inhibitor; Pharmacokinetics; Triazene

Indexed keywords

6 AMINOQUINAZOLINE DERIVATIVE; ANTINEOPLASTIC AGENT; DRUG METABOLITE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FD105AC; QUINAZOLINE DERIVATIVE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; ZRBA1;

ACETYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DNA DAMAGE; DRUG ABSORPTION; DRUG DEGRADATION; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SYNTHESIS; DRUG TARGETING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA;

ACETYLATION; ANIMALS; CELL PROLIFERATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; HUMANS; MALE; MASS SPECTROMETRY; MICE; PROSTATIC NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRIAZENES; TUMOR CELLS, CULTURED;

EID: 33646249624     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200602000-00007     Document Type: Article

References (37)

1. Modjtahedi H, Dean C. The receptor for EGF and its ligands: expression, prognostic value and target for therapy in cancer. Int J Oncol 1994; 4:277-296.
2. Xie H, Turner T, Wang MH, Singh RK, Siegal GP, Wells A. In vitro invasiveness of DU-145 human prostate carcinoma cells is modulated by EGF receptor-mediated signals. Clin Exp Metastasis 1995; 13:407-419.
3. Gordon AW, Pegues JC, Johnson GR, Kannan B, Auersperg N, Stromberg K. mRNA phenotyping of the major ligands and receptors of the EGF supergene family in human ovarian epithelial cells. Cancer Lett 1995; 89:63-71.
4. Bast RCJ, Pusztai L, Kerns BJ, MacDonald JA, Jordan P, Daly L, et al. Coexpression of the HER-2 gene product, p185HER-2, and epidermal growth factor receptor, p170EGF-R, on epithelial ovarian cancers and normal tissues. Hybridoma 1998; 17:313-321.
5. Scoccia B, Lee YM, Niederberger C, Ilekis JV. Expression of the ErbB family of receptors in ovarian cancer. J Soc Gynecol Invest 1998; 5:161-165.
6. Lamharzi N, Halmos G, Armatis P, Schally AV. Expression of mRNA for luteinizing hormone-releasing receptors and epidermal growth factor receptors in human cancer cell lines. Int J Oncol 1998; 12:671-675.
7. Meden H, Kuhn W. Overexpression of the oncogene c-erbB-2 (HER2, neu) in ovarian cancer: a new prognostic factor. Eur J Obstet Gynecol Reprod Biol 1997; 71:173-179.
8. Chen X, Yeung TK, Wang Z. Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3. Biochem Biophys Res Commun 2000; 277:757-763.
9. Simpson BJ, Bartlett JM, Macleod KG, Rabiasz G, Miller EP, Rae AL, et al. Inhibition of transforming growth factor alpha (TGF-alpha)-mediated growth effects in ovarian cancer cell lines by a tyrosine kinase inhibitor ZM 252868. Br J Cancer 1999; 79:1098-1103.
10. Yaish PA, Gazit P, Gilon C, Levitski A. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science 1988; 242:933-935.
11. Baselga J. New therapeutic agents targeting the epidermal growth factor receptor. J Clin Oncol 2000; 18:54S-59S.
12. Ciardiello F, Caputo R, Bianco R, Damianco V, Pomatico G, De Placido S, et al. Antitumour effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-sensitive tyrosine kinase inhibitor. Clin Cancer Res 2001; 6:2053-2063.
13. Dancey JE, Freidlin B. Targeting epidermal growth factor receptor - are we missing the mark? Lancet 2003; 362:62-64.
14. Lee JY, Park YK, Seo SH, Yang B, Park H, Lee YS. 7-Substituted-[1,4]dioxano[2,3-g]quinazolines as inhibitors of epidermal growth factor receptor kinase. Arch Pharm Med Chem 2002; 10:487-494.
15. Brahimi F, Matheson SL, Dudouit F, McNamee JP, Tari AM, Jean-Claude BJ. Inhibition of epidermal growth factor receptor-mediated signaling by 'Combi-Triazene' BJ2000, a new probe for combi-targeting postulates. J Pharmacol Exp Ther 2002; 303:238-246.
16. Qiu Q, Dudouit F, Matheson SL, Brahimi F, Banerjee R, McNamee JP, et al. The combi-targeting concept: a novel 3,3-disubstituted nitrosourea with EGFR tyrosine kinase inhibitory properties. Cancer Chemother Pharmacol 2003; 51:1-10.
17. Matheson SL, McNamee JP, Wang T, Alaoui-Jamali MA, Tari A, Jean-Claude BJ. The Combi-Targeting concept: dissection of the binary mechanism of action of the combi-triazene SMA41 in vitro and antiproliferative effects in vivo. J Pharmacol Exp Ther 2004; 311:1163-1170.
18. Matheson SL, Mzengeza S, Jean-Claude BJ. Synthesis of 1-[4-(m-tolyl)-amino-6-quinazolinyl]-3-[14C]-methyl triazene: a radiolabeled probe for the combi-targeting concept. J Label Compd Radiopharm 2003; 46:729-735.
19. Rachid Z, Brahimi F, Teoh N, Jean-Claude BJ. The combi-targeting concept: chemical dissection of the dual targeting properties of a series of 'combi-triazenes'. J Med Chem 2003; 46:4313-4321.
20. Qiu Q, Dudouit F, Banerjee R, McNamee JP, Jean-Claude BJ. Inhibition of cell signaling by the combi-nitrosourea FD137 in the androgen independent DU145 prostate cancer cell line. Prostate 2004; 59:13-21.
21. Banerjee R, Rachid Z, Jean-Claude BJ. Synthesis of a prodrug designed to release multiple inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase and an alkylating agent: a novel tumour targeting concept J Med Chem 2003; 46:5546-5551.
22. Matheson SL. The combi-targeting concept: a novel tumour targeting strategy [PhD Thesis]. Montreal: McGill University; 2003.
23. Matheson SL, McNamee JP, Jean-Claude BJ. The combi-targeting concept: intracellular fragmentation of the binary epidermal growth factor (EGFR)/DNA-targeting 'combi-triazene' SMA41. Biochem Pharmacol 2004; 67:1131-1138.
24. Brahimi F, Rachid Z, McNamee JP, Alaoui-Jamali MA, Tari AM, Jean-Claude BJ. Mechanism of a novel 'combi-triazene' engineered to possess a polar functional group on the alkylating moiety: evidence for enhancement of potency. Biochem Pharmacol 2005; 70:511-519.
25. Nells HJCF, Alry SC, Sinshelmer JE. Comparison of the alkylation of nicotinamide and 4-(p-nitrobenzyl)pyridine for the determination of aliphatic epoxides. Anal Chem 1982; 54:213-216.
26. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New colorimetric cytotoxicity assay for anti-cancer drug screening. J Natl Cancer Inst 1990; 82:1107-1112.
27. Matheson SL, McNamee J, Jean-Claude BJ. Design of a chimeric 3-methyl-1,2,3-triazene with mixed receptor tyrosine kinase and DNA damaging properties: a novel tumour targeting strategy. J Pharmacol Exp Ther 2001; 296:832-840.
28. LaFrance RJ, Manning HW, Vaughan K. Open-chain nitrogen compounds. Part XII. Methanolysis of 3-alkyl-3,4-dihydro-1,2,3-benzotriazin-4-ols: evidence for ring-chain tautomerism with the cytotoxic monoalkyltriazenes. Can J Chem 1987; 65:292-297.
29. Shealy YF, Krauth CA. Imidazoles. II. 5(or 4)-(Monosubstituted triazeno)imidazole-4(or 5)-carboxamides. J Med Chem 1966; 9:34-38.
30. Kolar GF, Maurer M, Wildschutte M. 5-(-3-Hydroxymethyl-3-methyl-1-triazeno imidazole-4-carboxamide is a metabolite of 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (DIG, DTIC NSC-45388). Cancer Lett 1980; 10:235-241.
31. Lin AJ, Loo TI. Synthesis and antitumor activity of halogen-substituted 4-(3,3-dimethyl-1-triazeno)quinolines. J Med Chem 1978; 21:268-272.
32. Saleem A, Brown GD, Brady F, Aboagye EO, Osman S, Luthra SK et al. Metabolic activation of temozolomide measured in vivo using positron emission tomography. Cancer Res 2003; 63: 2409-2415.
33. Meyer UA, Zanger UM. Molecular mechanism of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 1997; 37:269-296.
34. Blum M, Demierre A, Grant DM, Heim M, Meyer UA. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci USA 1991; 88:5237-5241.
35. Boobis AR. Molecular basis for differences in susceptibility to toxicants: introduction. Toxicol Lett 1992; 64/65:109-113.
36. Grant DM, Goodfellow GH, Sugamori KS, Durette K. Pharmacogenetics of the human arylamine N-acetyltransferases. Pharmacology 2000; 61:204-211.
37. Yacoub A, McKinstry R, Hinman D, Chung T, Dent P, Hagan MP. Epidermal growth factor and ionizing radiation up-regulate the DNA repair genes XRCC1 and ERCC1 in DU145 and LNCaP prostate carcinoma through MARK signaling. Radiat Res 2003; 159:439-452.